Dossier
Entrada Therapeutics
Coverage of Entrada Therapeutics in the Nexus archive.
- STAT+: Next-gen Duchenne drug from Entrada disappoints
Entrada Therapeutics' next-generation drug for Duchenne muscular dystrophy disappointed in an early trial, raising questions about the company's competitiveness. The drug is designed to help patients produce shortened but still functional forms of dystrophin. Scientists have devised ways to redesign these molecules for better results.